The EORTC 58951 trial for children with average risk acute lymphoblastic leukemia or non-Hodgkin lymphoma evaluated dexamethasone versus prednisolo
Results from a clinical trial funded by the Medical Research Council (MRC) and the European Organisation for Research and Treatment of Cancer (EORTC) show that women whose ovarian cancer has returned can delay chemotherapy treatment until symptoms appe
Following the success of the first EORTC-EANO Conference in 2009 in Hungary, we are extremely proud to announce on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group and the European Association of Neuro-
The standard of care for patients with advanced ovarian cancer has been primary debulking surgery; ovarian carcinoma is often not diagnosed until it is at an advanced stage.
The 12th Joint ECCO-AACR-EORTC-ESMO Workshop on “Methods in Clinical Cancer Research 2010” was held on 19 – 25 June 2010 in Waldhaus Flims, Switzerland. This conference was jointly organized by the European CanCer Organisation (ECCO), American Association for Cancer Research (AACR), the European Organisation for the Research and Treatment of Cancer (EORTC), and European Society for Medical Oncology (ESMO). The EORTC participated for the first time as a full partner of this workshop.
PROBE, Patient Reported Outcomes and Behavioral Evidence, is a project designed to illuminate many critical albeit underappreciated topics that have a significant impact on psychosocial and Health Related Quality Of Life (HRQOL) issues in the care of patients with cancer. PROBE strives to develop a deeper understanding of these issues not only in relation to common cancer disease sites such as breast and colorectal, but also in rarer diseases such as glioblastoma, small cell lung cancer, and mesothelioma.
A newly founded EORTC task force, the Endocrine Tumors Task Force (EnTF) is taking shape at the EORTC. This task force will have an estimated potential access to more than 2000 thyroid carcinomas and over 600 adrenal cancers every year. The EnTF currently involves institutions in Belgium, Denmark, Egypt, France, Germany, Greece, Italy, Poland, Portugal, Slovenia, Switzerland, The Netherlands, and the United Kingdom, and Slovenia, and it is continuing to expand throughout Europe.
This past June, Dr. Leen Verleye completed a three year stay at EORTC Headquarters as a Research Fellow in the EORTC Gynecological Cancer Group (GCG). During her fellowship Dr.
5th EORTC-NCI-ASCO Annual Meeting on “Molecular Markers in Cancer” (ENASCO) will be held 26 – 29 October 2011, at the SQUARE Meeting Centre in Brussels, Belgium.
